Blackstone Inc
SABS icon

Blackstone Inc’s SAB Biotherapeutics SABS Stock Holding History

Blackstone Inc’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.29M Sell
860,170
-1,283,415
-60% -$5.12M 0.01% 154
2025
Q4 		$8.02M Buy
+2,143,585
New +$7.05M 0.03% 103

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Blackstone Inc's SABS Position: Q1 2026 in Review

Blackstone Inc reduced its SAB Biotherapeutics (SABS) stake by 60% in Q1 2026, selling an estimated $5.12M and leaving 860,170 shares worth $3.29M. The position accounts for 0.01% of the portfolio, ranked #154.

Blackstone Inc first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.02M in Q4 2025. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Blackstone Inc held 860,170 shares of SAB Biotherapeutics worth $3.29M as of Q1 2026.
  • Blackstone Inc sold 1,283,415 SAB Biotherapeutics shares in Q1 2026, an estimated $5.12M.
  • SAB Biotherapeutics made up 0.01% of Blackstone Inc's portfolio in Q1 2026, its #154 holding.
  • Blackstone Inc first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • Blackstone Inc's SAB Biotherapeutics position peaked at $8.02M in Q4 2025.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.